|
|
||||||||||
|
J Am Coll Cardiol, 2000; 36:1097-1103 © 2000 by the American College of Cardiology Foundation |




* UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
New England Research Institutes, Watertown, Massachusetts, USA
Centre Hospitalier de la Citadelle, Liège, Belgium
Mt. Sinai Medical Center, New York, New York, USA
|| St. LukesRoosevelt Hospital, New York, New York, USA
Manuscript received February 16, 2000; revised manuscript received June 2, 2000, accepted June 7, 2000.
Reprint requests and correspondence: Dr. Daniel M. Shindler, 1 Gloucester Court, East Brunswick, New Jersey 08816
shindler{at}umdnj.edu
OBJECTIVES
We sought to examine the role of diabetes mellitus in cardiogenic shock (CS) complicating acute myocardial infarction (AMI) in the SHOCK Trial Registry.
BACKGROUND
The characteristics, outcomes and optimal treatment of diabetic patients with CS complicating AMI have not been well described.
METHODS
Baseline characteristics, clinical and hemodynamic measures, treatment variables, shock etiologies and comorbid conditions were compared for 379 diabetic and 784 nondiabetic patients. Logistic regression was used to examine the association between diabetes and in-hospital mortality, after adjustment for baseline differences.
RESULTS
Diabetics were less likely than nondiabetics to undergo thrombolysis (28% vs. 37%; p = 0.002) or attempted revascularization (40% vs. 49%; p = 0.008). The survival benefit for diabetics selected for percutaneous or surgical revascularization (55% vs. 19% without revascularization) was similar to that for nondiabetics (59% vs. 25%). Overall unadjusted in-hospital mortality was significantly higher for diabetics (67% vs. 58%; p = 0.007), but diabetes was only a borderline predictor of mortality after adjustment for baseline and treatment differences (odds ratio for death, 1.36; 95% confidence interval, 1.00 to 1.84; p = 0.051).
CONCLUSIONS
Diabetics with CS complicating AMI have a higher-risk profile at baseline, but after adjustment, diabetics have an in-hospital survival rate that is only marginally lower than that of nondiabetics. Diabetics who undergo revascularization derive a survival benefit similar to that of nondiabetics.
| ||||||||||||||||||||||
This article has been cited by other articles:
![]() |
T. Ohno, S. Takamoto, and N. Motomura Diabetic Retinopathy and Coronary Artery Disease From the Cardiac Surgeon's Perspective Ann. Thorac. Surg., February 1, 2008; 85(2): 681 - 689. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. F. Luscher, M. A. Creager, J. A. Beckman, and F. Cosentino Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part II Circulation, September 30, 2003; 108(13): 1655 - 1661. [Full Text] [PDF] |
||||
![]() |
J. A. Beckman, M. A. Creager, and P. Libby Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management JAMA, May 15, 2002; 287(19): 2570 - 2581. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |